ImageneBio (IMA) EBT (2020 - 2025)

ImageneBio has disclosed EBT across 6 years of filings, most recently posting -$24.9 million for Q3 2025.

• EBT for Q3 2025 came in at -$24.9 million, down 680.8% year-over-year; the trailing twelve-month figure through Sep 2025 was -$51.0 million (up 3.07% YoY), and the FY2024 annual result was -$49.1 million, up 28.17% from the prior year.
• EBT came in at -$24.9 million for Q3 2025 at ImageneBio, down from -$2.8 million in the prior quarter.
• In the past five years, EBT ranged from a high of $2.8 million in Q4 2021 to a low of -$24.9 million in Q3 2025.
• The 5-year median for EBT is -$14.5 million (2021), against an average of -$13.4 million.
• Across the five-year window, EBT surged 110.74% in 2021 and sank 680.8% in 2025, its largest moves.
• ImageneBio's EBT stood at $2.8 million in 2021, then slumped by 604.0% to -$14.1 million in 2022, then sank by 39.4% to -$19.7 million in 2023, then grew by 11.83% to -$17.3 million in 2024, then sank by 43.44% to -$24.9 million in 2025.
• The last three EBT figures came in at -$24.9 million (Q3 2025), -$2.8 million (Q2 2025), and -$6.1 million (Q1 2025), per Business Quant data.